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Animal genomes contain endogenous viral sequences, such as endogenous retroviruses and 21 
retrotransposons. Recently, we and others discovered that non-retroviral viruses also have 22 
been endogenized in many vertebrate genomes. Bornaviruses belong to the Mononegavirales 23 
and have left endogenous fragments, called endogenous bornavirus-like elements (EBLs), in 24 
the genomes of many mammals. The striking features of EBLs are that they contain relatively 25 
long open reading frames (ORFs) which have high sequence homology to the extant 26 
bornavirus proteins. Furthermore, some EBLs derived from bornavirus nucleoprotein 27 
(EBLNs) have been shown to be transcribed as mRNA and probably are translated into 28 
proteins. These features lead us to speculate that EBLs may function as cellular co-opted 29 
genes. An EBLN element in the thirteen-lined ground squirrel (Ictidomys tridecemlineatus) 30 
genome, itEBLN, encodes an ORF with 77% amino acid sequence identity to the current 31 
bornavirus N. In this study, we cloned itEBLN from the ground squirrel genome and 32 
investigated its involvement in Borna disease virus (BDV) replication. Interestingly, itEBLN, 33 
but not a human EBLN, co-localized with the viral factory in the nucleus and appeared to 34 
affect BDV polymerase activity by being incorporated into the viral ribonucleoprotein. Our 35 
data show that, as with certain endogenous retroviruses, itEBLN potentially may inhibit 36 
infection by related exogenous viruses in vivo. 37 
 38 
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Significance statement 41 
Sequences derived from ancient viruses have been shown to make up a substantial part of 42 
animal genomes. Bornaviruses, a genus of non-segmented, negative-sense RNA virus, have 43 
also left their DNA copies in the genomes of quite a number of vertebrate lineages. Recent 44 
studies have demonstrated that some endogenous bornavirus elements (EBLs) may have 45 
acquired functions in their hosts as a result of exaptation. In this study, we show that protein 46 
encoded by an EBL in the thirteen-lined ground squirrel genome efficiently blocks infection 47 
and replication of extant bornavirus. This is the first report showing that endogenous elements 48 
derived from non-retroviral RNA viruses may have been co-opted for a new function of 49 





Endogenous retroviruses have accumulated in the genomes of many organisms over 53 
evolutionary time and occupy about 8% of the human genome (1). Although almost all 54 
endogenous retroviruses in animal genomes appear to lack intact open reading frames (ORFs) 55 
and are not expressed in somatic tissues, some retain the potential to express mRNA and even 56 
produce the proteins they encode (2, 3). There is mounting evidence that expression of human 57 
endogenous retroviruses (HERVs) is associated with some autoimmune diseases, cancers and 58 
schizophrenia, as well as viral infections (4-6), suggesting that the induction of HERVs may 59 
be linked to immunological aberrations in the host. In addition, it has been reported that 60 
endogenous retroviruses have the ability to recombine with exogenous or other endogenous 61 
retroviruses to produce intact infectious viruses (7, 8). These observations indicate that the 62 
expression of endogenous retroviruses may cause deleterious consequences directly to the 63 
hosts.     64 
On the other hand, recent studies have revealed clearly that endogenous retroviruses 65 
have been co-opted to play new and beneficial roles in their hosts (9, 10). For instance, in 66 
mammals, envelope genes from endogenous retroviruses are involved in the formation of the 67 
placenta during the fusion of syncytiotrophoblast cells (9, 11). In addition, a retroviral-like 68 
aspartic protease, skin aspartic protease, SASPase, is known to play a key role in determining 69 
the texture of skin by modulating the degree of hydration in mammals (12, 13). Furthermore, 70 
it has been known for decades that endogenous retrovirus-derived elements, such as Friend 71 
virus susceptibility 1 (Fv1) gene and endogenous fragments from Jaagsiekte sheep retrovirus 72 
(enJSRV), protect host cells from infection by exogenous retroviruses (10, 14, 15). These 73 
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lines of evidence suggest that evolution has favored persistence of endogenous retroviral 74 
elements that have the potential to protect their hosts against related viruses. 75 
Recent advances in the availability of genomic sequences from many animal species, as 76 
well as the development of tools for sequence comparisons, have revealed that non-retroviral 77 
viruses also have endogenized in many mammalian species (16-18). Bornavirus, an enveloped, 78 
nonsegmented, negative-strand RNA virus in the order Mononegavirales, is unique among 79 
animal RNA viruses, not only because it replicates in the cell nucleus but also because it 80 
readily establishes a long-lasting persistent infection in the absence of overt cytopathogenesis 81 
(19). Although bornavirus does not integrate into the host genome during its replication cycle, 82 
interestingly, we and others found recently that DNA sequences derived from ancient 83 
bornaviruses are endogenized in the genomes of many vertebrate species, including humans 84 
(16, 17). The endogenous fragments of bornavirus in mammalian genomes originate 85 
predominantly from the region encoding the viral nucleoprotein (N), which encapsidates viral 86 
genomic RNA to form nucleocapsids, and we therefore designated them endogenous 87 
bornavirus-like nucleoproteins (EBLNs) (16).     88 
In a previous study, we showed that EBLNs from the human and thirteen-lined ground 89 
squirrel (TLS) (Ictidomys tridecemlineatus) genomes, named hsEBLN and itEBLN, 90 
respectively, have significant sequence similarity to the N ORFs of extant mammalian 91 
bornaviruses, Borna disease virus (BDV). The elements, hsEBLN-1 and -2, which are located 92 
in chromosomes 10 and 3 of the human genome, respectively, encode ORFs with an overall 93 
41% amino acid sequence identity to BDV N (16). itEBLN also has an intact ORF and shows 94 
approximately 77% amino acid sequence identity to N. Furthermore, it has been shown that 95 
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some hsEBLNs, including hsEBLN-1 and -2, are expressed as RNA and that a predicted 96 
mRNA transcript of itEBLN is provided by NCBI RefSeq (XM_005342477). Interestingly, 97 
we have found that long terminal repeats (LTR-1C and LTR-21B) from endogenous retroviruses 98 
exist in close proximity and upstream of itEBLN ORF (20). In fact, we could detect the 99 
predicted transcripts of itEBLN in several tissue samples from both breeding and 100 
wild-captured TLSs by RT-PCR (Supplementary Fig. S1). From these observations, it is 101 
tempting to speculate that EBLNs encode functional proteins as a consequence of exaptation 102 
or co-option by their hosts.  103 
In this study, we cloned hsEBLN-1 and itEBLN sequences from the human and TLS 104 
genomes, respectively, to determine whether these EBLNs encode potentially functional 105 
proteins. We found that the protein encoded by itEBLN, but not hsEBLN-1, colocalizes with 106 
the viral factory in the nucleus and markedly decreases infection and the replication of 107 
exogenous BDV. Furthermore, the protein encoded by itEBLN appeared to be incorporated 108 
into the viral ribonucleoproteins (RNPs) in infected cells. These results suggest that, like 109 
some endogenous retroviruses, itEBLN has the potential as a co-opted gene in the host to 110 




Expression and reconstruction of EBLN elements from the human and ground squirrel 115 
genomes.   To investigate the potential roles of the EBLN elements in the human and TLS 116 
genomes, we first amplified EBLN sequences from the genomic DNAs and cloned the 117 
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products into expression vectors. Although the expression of hsEBLN-1 and itEBLN has been 118 
predicted in previous studies (16, 18), the structure and transcription initiation sites of the 119 
EBLN RNAs have not been characterized. In this study, therefore, we cloned only the 120 
homologous regions to BDV N. To detect the expressed EBLN products, an HA-tag was 121 
fused to the N-terminus of the coding sequences. At first, we transfected the plasmids into 122 
human OL cells and investigated the expression of the reconstituted proteins by western 123 
blotting at 24 h posttransfection. As shown in Fig. 1A, expression of the recombinant proteins 124 
was detected as approximately 35 to 40 kDa products, indicating that the EBLNs may have 125 
the ability to stably express the proteins in mammalian cells. In addition, we carried out 126 
immunofluorescence assays to examine the subcellular localization of the proteins. As shown 127 
in Fig. 1B, while BDV N clearly localizes in the nucleus, itEBLN and hsEBLN-1 appear to be 128 
distributed predominantly in the cytoplasm of the transfected cells, probably because these 129 
proteins lack the nuclear localization signal (NLS), which is present in the N-terminus of 130 
BDV N (see Fig. 5).  131 
Next, we transfected the EBLN plasmids into OL cells persistently infected with BDV. 132 
In a previous study, we demonstrated that BDV generates dot-like structures, called vSPOT 133 
(viral speckles of transcripts), in the nucleus (21). The vSPOT is the viral factory, in which 134 
essential events in the BDV replication cycle take place and could be the same structured 135 
nuclear bodies having the same function, as Joest-Degen inclusion bodies in vivo (22-24). 136 
Despite the lack of a nuclear localization activity, itEBLN was strongly redistributed to 137 
vSPOTs in the nucleus, as does N (Fig. 1C, arrowheads). On the other hand, hsEBLN-1 138 
seemed to be not relocated in the infected cells. This observation suggests that itEBLN, but 139 
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not hsEBLN-1, may have the potential to interact with the viral components in the infected 140 
cells, leading to colocalization with vSPOT in the nucleus. 141 
 142 
itEBLN inhibits BDV replication in persistently infected cells.   In a previous study, Geib 143 
et al. (2003) revealed that transient expression of BDV P, but not N, inhibits viral replication 144 
(25) in Vero cells persistently infected with BDV. Therefore, we next investigated whether 145 
expression of hsEBLN-1 and itEBLN affects BDV replication in persistently infected cells. 146 
To evaluate viral transcription/replication, we measured the level of viral RNAs in cells 147 
transfected with the EBLN plasmids. Consistent with previous reports, transient expression of 148 
N in persistently infected OL cells did not exert any effect on BDV replication (Fig. 1D and 149 
1E). In contrast, intriguingly, expression of itEBLN, but not hsEBLN-1, significantly reduced 150 
the levels of both viral genomic and mRNA at 48 h posttransfection (Fig. 1D and 1E). This 151 
result suggested that, unlike N, itEBLN could inhibit both the transcription and replication of 152 
BDV. 153 
 154 
Expression of itEBLN confers resistance to exogenous BDV infection.   Previous studies 155 
revealed that expression of BDV N protects cells from subsequent infection by BDV (25). 156 
Although the detailed mechanism of this resistance to superinfection has not been elucidated, 157 
it is assumed that an early step of BDV infection, such as nuclear transport of viral RNP, 158 
intranuclear dissemination or initiation of viral replication, may be interfered with by the 159 
overexpression of the viral nucleocapsid component (25). To determine whether itEBLN can 160 
also affect BDV infection, we established OL cell lines stably expressing itEBLN or 161 
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hsEBLN-1. In this experiment, we also generated a plasmid, pNL-itEBLN, in which itEBLN 162 
is fused with the NLS of BDV N at the N-terminus (Fig. 2A), in order to investigate the effect 163 
of nuclear localization of the protein. As for N, the product of pNL-itEBLN clearly localized 164 
in the nuclei of transiently transfected cells (Fig. 2B). We then infected the cell lines with 165 
cell-free virions of recombinant BDV (rBDV) expressing GFP, rBDV P/M-GFP, with an 166 
M.O.I. of 0.1 and monitored the propagation of GFP for at least 3 weeks. As shown in Fig. 2C 167 
and 2D, the expression of itEBLN and NL-itEBLN, but not hsEBLN-1, nearly completely 168 
protects the cells against BDV infection for the observation period, as does N, suggesting that 169 
itEBLN protects against BDV infection in the nucleus  170 
We next performed cocultivation experiments using the EBLN-expressing OL cell lines 171 
and Vero cells persistently infected with rBDV P/M-GFP, to investigate whether itEBLN can 172 
also inhibit the cell-to-cell spread of the infection, which is presumably the main route of 173 
BDV transmission. Repeated experiments revealed that, despite incomplete protection of the 174 
cells expressing N, itEBLN constructs were almost completely resistant to virus infection (Fig. 175 
3A and 3B). This indicated that itEBLN could have a strong inhibitory effect on BDV 176 
infection, even following cell-to-cell transmission. To exclude the possibility that the NLS 177 
region (amino acids 1 to 38) of BDV N in the constructs has an effect on BDV replication, we 178 
also conducted the experiments using two different plasmids, pNLsv-itEBLN and 179 
pNL-DsRed, in which itEBLN and DsRed were fused with SV40 and BDV N NLS at the 180 
N-terminus, respectively (Supplementary Fig. S2). The results in Supplementary Fig. S3 show 181 
that the NLS region of N is not involved in the inhibitory effect of NL-itEBLN on BDV 182 




Incorporation of itEBLN into BDV RNP.   The results shown above suggest the 185 
possibility that the itEBLN protein may be directly incorporated into BDV RNP, resulting in 186 
inhibition of viral replication. To test this possibility, we performed an immunoprecipitation 187 
analysis using BDV-infected cells transfected with the EBLN plasmids. At 24 h 188 
posttransfection, the cell extracts were immunoprecipitated with anti-HA antibody and the 189 
viral RNP components were detected by western blotting and RT-PCR. As shown in Fig. 4A, 190 
BDV genomic RNA, as well as BDV P, was clearly precipitated with itEBLN and N, whereas 191 
hsEBLN-1 seemed not to interact with BDV RNP in the cells. This observation revealed that 192 
itEBLN may be efficiently incorporated into the viral RNP in infected cells. 193 
 194 
itEBLN inhibits BDV polymerase activity in a minireplicon system.   We next 195 
determined whether itEBLNs can directly affect the polymerase activity of BDV. To this end, 196 
we used a minireplicon system of BDV, which synthesizes recombinant BDV nucleocapsids 197 
containing an artificial, minigenome reporter RNA, following transfection of expression 198 
plasmids encoding BDV N, P, L, and the minigenome (26). We carried out the minireplicon 199 
assay in the presence or absence of plasmids expressing itEBLN. Consistent with previous 200 
observation (26), the viral polymerase activity was strongly inhibited when BDV X was 201 
cotransfected with the minireplicon constructs (Fig. 4B). Interestingly, despite that BDV N 202 
could not inhibit the polymerase activity of the minireplicon, all of the itEBLN constructs, 203 
including itEBLN-M2, which is translated from the AUG codon at amino acid position 132 in 204 
the itEBLN sequence (see Fig. 5), efficiently decreased the polymerase activity in the system 205 
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(Fig. 4B). Altogether, these results suggest that itEBLN acts as a dominant negative inhibitor 206 
of N by being incorporated into the viral RNP. 207 
 208 
The putative tetramer and RNA interaction domains of BDV N are conserved in itEBLN. 209 
Previous studies revealed that BDV N contains several signal sequences, including the NLS 210 
and nuclear export signal (NES), and putative P binding sites (27-29). Furthermore, structural 211 
studies of BDV N determined the amino acids essential for homotetramer formation and 212 
interaction with viral RNA (30, 31). To predict the function of itEBLN as a dominant negative 213 
inhibitor of N, we aligned the amino acid sequences of BDV N and itEBLN. As shown in Fig. 214 
5, BDV N contains an NLS in the N-terminal region, whereas itEBLN lacks a homologous 215 
sequence in that region. On the other hand, putative binding sites for P (PBS-1 and -2) seem 216 
to be highly conserved between itEBLN and BDV N (Fig. 5). In addition, the sequences 217 
predicted to be involved in tetramerization of BDV N also seem to be conserved in the 218 
sequence of itEBLN, with the exception of the sequence in the N-terminus of BDV N (Fig. 5, 219 
asterisks). Furthermore, we also found that the corresponding residues essential for interaction 220 
with the viral RNA (K164, R165, K242 and R297) (Fig. 5, arrowheads) are well conserved in 221 
itEBLN. A structural model based on BDV N also revealed that the regions surrounding the 222 
RNA interaction sites are also conserved in itEBLN (Supplementary Fig. S4), suggesting that 223 






In this study, we showed that the protein expressed from an endogenous bornavirus fragment 228 
from the TLS genome, itEBLN, is incorporated into BDV RNPs and inhibits BDV replication. 229 
This conclusion is supported by the following observations: first, we found that the itEBLN 230 
protein was colocalized with the viral factory of BDV in the nucleus. Second, the expression 231 
of this protein markedly reduced the replication level of BDV in persistently infected cells. 232 
Furthermore, the cells stably expressing the itEBLN protein were completely resistant to 233 
infection by exogenous BDV through both the cell-free and cell-to-cell routes. Third, we 234 
showed that the itEBLN protein can precipitate BDV RNP components, including viral 235 
genomic RNA, in infected cells. Finally, co-expression of itEBLN reduced BDV polymerase 236 
activity using the minireplicon system. To our knowledge, this is the first report that an 237 
endogenous, non-retroviral virus efficiently inhibits infection by the related exogenous virus.  238 
In this study, we employed an overexpression system of recombinant itEBLN with 239 
human cell culture systems. Thus, in order to demonstrate the host-specific exaptation of 240 
itEBLN, it would be necessary to investigate whether TLSs actually exhibit resistance to 241 
BDV infection. At present, however, we could neither find any available cultured cells of 242 
TLSs nor establish experimental infection using TLSs. On the other hand, we could detect the 243 
expression of predicted mRNA of itEBLN in tissue samples from both breeding and 244 
wild-captured TLSs by RT-PCR (Supplemental Figure S1A and B). The immunoblot analysis 245 
using a BDV N-specific polyclonal antibody showed only a faint band at the predicted size in 246 
the heart samples (Supplemental Figure S1C). Although the expression of itEBLN protein 247 
remained obscure due to the specificity of the antibody, given that the itEBLN mRNAs are 248 
efficiently translated into the protein in the squirrel cells, itEBLN may protect BDV infection 249 
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in vivo. We will continue to make an effort to establish infection systems of TLSs with BDV. 250 
Our results showed that the expression of itEBLN not only reduces viral replication but 251 
also blocks de novo BDV infection. Immunofluorescence and immunoprecipitation assays 252 
indicated that the itEBLN protein interacted efficiently with BDV RNP in the infected cells. 253 
Among the RNP components, the most likely candidate is the N protein, because BDV N is 254 
known to tightly assemble as a homotetramer (30). BDV N forms the nucleocapsid, which 255 
serves as the template for RNA synthesis with the L and P proteins (31, 32), strongly 256 
suggesting that itEBLN participates in heteromultimerization with BDV N. It has been 257 
determined that the residues predicted to be important for tetramer formation by N are located 258 
in the N- and C-termini of the protein (Fig. 5) (30). An amino acid comparison between the 259 
itEBLN protein and BDV N revealed that the identity between BDV N and itEBLN may be 260 
sufficient to permit heteromultimerization. It is highly likely, therefore, that the itEBLN 261 
protein efficiently co-assembles with BDV N into viral nucleocapsids in infected cells. In a 262 
previous study, Geib et al. (25) demonstrated that transient expression of recombinant N in 263 
BDV persistently infected cells does not inhibit BDV replication, even though the transduced 264 
N was colocalized with the viral factory in the nucleus. This observation was also confirmed 265 
in our experiments shown in Fig. 1, suggesting that the itEBLN may act like a dominant 266 
negative mutant of N in the viral nucleocapsids and exert a deleterious effect on the viral 267 
replication. In fact, a numbers of substitutions, especially at the N-terminus, were found in the 268 
itEBLN sequence (Fig. 5). Such heterogeneity might destabilize tetramer formation or the 269 
interaction with viral RNAs, leading to inhibition of viral polymerase activity.  270 
Alternatively, it may be possible that the itEBLN protein directly interacts with P and 271 
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inhibits the functions of P. In fact, the sequences corresponding to the P-binding sites in N 272 
have been shown to be well conserved in itEBLN. P plays important roles in viral replication, 273 
as a viral polymerase cofactor and in nucleocytoplasmic shuttling of the viral nucleocapsid 274 
(32-34). Although the intracellular distribution of P seems to be not altered by overexpression 275 
of itEBLN in the cells (Fig. 1C), the interaction between P and itEBLN may affect the 276 
dynamics of P in the infected cells. Furthermore, we previously demonstrated that expression 277 
of P regulates the translation efficiency of BDV X, which is a negative regulator of BDV 278 
polymerase (35). Thus, it may be also possible that their interaction affects the translation 279 
efficiency of X, resulting in the inhibition of polymerase activity of BDV. Together, it is 280 
conceivable that the effect of itEBLN on BDV replication may be multifaceted, via 281 
interaction with both N and P. Further experiments should be necessary to understand the 282 
mechanism of the inhibitory effect of itEBLN on BDV replication.  283 
Our results may reveal an intriguing strategy for inhibition of exogenous virus infection 284 
by endogenous viral fragments. Previous studies clearly demonstrated that endogenous viral 285 
products are efficiently interacted into the capsids of incoming, genetically related viruses, 286 
resulting in inhibition of viral replication. A well-studied example is the Fv1 gene in mice. 287 
Fv1 originated from the gag gene of an ancient retrovirus, which was endogenized several 288 
million years ago into the genome of a common ancestor of mice and is known to restrict 289 
infection by specific strains of MLV (14, 36). Although the amino acid sequence of Fv1 is 290 
distant from the restricted MLVs, recent studies clearly indicate that direct interaction of Fv1 291 
with the capsid protein of MLV induces the anti-MLV function of Fv1 (37). Another instance 292 
is the enJSRV. This endogenous virus is known to inhibit exogenous JSRV infection by two 293 
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different mechanisms (38). First, the envelope protein encoded by enJSRVs is expressed and 294 
binds to the cellular receptors used by JSRV (39). On the other hand, the Gag protein 295 
expressed by enJSRVs is also known to have deleterious effects on the replication of 296 
exogenous JSRV (15). A misfolded Gag protein of enJSRVs co-assembles with JSRV Gag and 297 
forms chimeric viral capsids, which are degraded by the proteasome system of the infected 298 
cells (40). In addition, Monde et al. have recently demonstrated that the Gag proteins of an 299 
endogenous betaretrovirus co-assemble with a distinct retrovirus, HIV-1, Gag protein to 300 
modulate the late phase of HIV-1 replication (41). Together with our observation that itEBLN 301 
also has the ability to form nucleocapsids with BDV N, interaction of endogenous viral 302 
products into the capsids or nucleocapsids of incoming exogenous viruses may be an effective 303 
way to regulate virus infections.  304 
Recent studies have demonstrated that the human genome contains many intrinsic 305 
factors that prevent viral infection (10, 42). Such factors could be acquired during evolution 306 
as consequences of the battle between viruses and their hosts. There is no doubt that the arms 307 
race between the host and virus has affected the evolution of both. In addition to the 308 
sophistication of the immune system, host organisms must have acquired many genes to 309 
overcome infection by pathogens over many generations of evolution. Exaptation is the 310 
co-opting of exogenous sequences as new genes, with functions distinct from their original 311 
purpose, into the genome (10, 43). The co-option of endogenous retroviruses as anti-viral 312 
factors is a good example of such exaptation. Until now, retroviruses were considered to be 313 
the only virus family that has been co-opted as new functional genes in the host genomes. Our 314 
results strongly suggest that exaptation by non-retroviral viral genes may have occurred 315 
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during the co-evolution of bornaviruses and their hosts.  316 
At present, some EBLNs from human and non-human primate genomes, including 317 
hsEBLN-1 and hsEBLN-2, have been shown to express RNAs that potentially encode 318 
proteins (16, 44). Although we could not demonstrate an inhibitory effect of the hsEBLN-1 319 
protein on the BDV replication, the possibilities that hsEBLN-1 plays roles in the cellular 320 
environment or acts at the level of RNA remain to be elucidated. On the other hand, 321 
hsEBLN-2 has been shown to express protein in human cells (44). A recent study also 322 
revealed that hsEBLN-2 is a candidate gene of the recurrent 3p12-p14 loss in cervical cancer 323 
and could be a novel tumour suppressor in cervical cancer (45). The human EBLNs are 324 
considered to have been generated 40 to 45 million years ago. Nevertheless, relatively long 325 
ORFs are conserved in these elements, especially hsEBLN-1 and -2, and these have a high 326 
level of amino acid identity with the N protein of current bornaviruses (16). These 327 
observations suggest the intriguing possibility that hsEBLN-1 and -2 have been adapted 328 
during evolution with new functions in the host cells. We are currently working on 329 
understanding the co-opted roles of the EBLNs, as well as other endogenous non-retroviral 330 
elements, in mammalian genomes. These studies could provide new insights into the 331 
co-evolution and between viruses and their hosts and the co-option of new genes in hosts 332 
following infection by exogenous viruses.  333 
 334 
 335 
Materials and Methods 336 
Cells.   OL (human oligodendroglioma) and Vero cell lines were cultured in Dulbecco's 337 
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modified Eagle's medium (DMEM)-high glucose (4.5%) supplemented with 5% fetal bovine 338 
serum (FBS) and 4 mM glutamine. HEK293T cells were cultured in DMEM-low glucose 339 
(1.0%) supplemented with 10% FBS. OL cells persistently infected with BDV strain huP2br 340 
(OL/BDV) were cultured using the same conditions as the parental cell line. The cell lines 341 
stably expressing hsEBLN-1, itEBLN or BDV N were established by the limiting dilution and 342 
maintained in culture medium with Zeocin (Invitrogen) or G418 (Invitrogen).  343 
 344 
Virus Infection.   OL cell lines stably expressing the EBLN constructs were infected with 345 
cell-free rBDV P/M-GFP (46) virions at an M.O.I of 0.1. After absorption for 1 h, the cells 346 
were washed with phosphate-buffered saline (PBS) and passaged within 2 or 3 days. In 347 
addition, the OL cell lines were cocultured with Vero cells persistently infected with rBDV 348 
P/M-GFP. Three days after the co-cultivation, the cells were treated by Zeocin or G418 to 349 
eliminate the Vero cells. The infection rates of the cells were determined by measuring GFP 350 
expression using a FACSCalibur flow cytometer (BD Biosciences) or Tali Image-Based 351 
Cytometer (Invitrogen). 352 
 353 
Minireplicon Assay.   Minireplicon assays were carried out according to Yanai et al. (26). 354 
Briefly, HEK293T cells were seeded in 12-well plates and transfected with expression 355 
plasmids of BDV N (0.1 μg), P (0.01 μg), RNA-dependent RNA polymerase (L) (0.1 μg) and 356 
Pol II-driven minigenome plasmids (0.1 μg), with or without EBLN and BDV X expression 357 
plasmids (0.5 μg), using Lipofectamine 2000 (Invitrogen). 48 h later, the cells were lysed and 358 
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Figure legends  480 
 481 
Fig. 1. Expression of itEBLN inhibits BDV replication in transfected human cells.  (A) 482 
Expression of recombinant EBLN proteins in transiently transfected OL cells. The HA-fused 483 
itEBLN, hsEBLN-1 and BDV N constructs were transfected into OL cells and the expressed 484 
proteins were detected by western blotting using anti-HA antibody. (B and C) Subcellular 485 
localization of recombinant EBLNs in transfected cells. The expression plasmids were 486 
transfected into uninfected (B) and OL cells persistently infected with BDV (C), and the 487 
distributions of EBLN proteins and BDV P were visualized by immunofluorescence assay 488 
with anti-HA (red) and anti-P (green) antibodies, respectively. Cells were counterstained with 489 
DAPI. Scale bar, 10 μm. Arrowheads in (C) indicate bornavirus viral factories, vSPOT. (D 490 
and E) Expression of itEBLN decreases the level of BDV RNAs in persistently infected cells. 491 
Forty-eight hour after transfection of the indicated constructs, the amounts of BDV genomic 492 
RNA (D) and mRNA (E) were quantified by real-time RT-PCR. Empty indicates the cells 493 
transfected with an empty vector. The values are presented as the mean ± SE of three 494 
independent experiments. Statistical significance was analyzed by the two-tailed t test. *p < 495 
0.05, **p < 0.01. 496 
 497 
Fig. 2. Expression of itEBLN in human cells inhibits BDV infection.  (A) Schematic 498 
representations of the recombinant proteins of BDV N and itEBLN. An expression plasmid, 499 
pNL-itEBLN, was generated by fusing the NLS of BDV N (amino acids 1 to 38) to the 500 
N-terminus of itEBLN ORF. (B) Subcellular localization of NL-itEBLN in the transiently 501 
24 
 
transfected BDV/OL cells. Scale bar, 10 μm. (C) OL cells stably expressing pHA-N, pitEBLN, 502 
pNL-itEBLN and phsEBLN-1 were inoculated with cell-free rBDV expressing GFP at an 503 
M.O.I. of 0.1. GFP expression was monitored by fluorescence microscopy. The cells were 504 
photographed 4 days after infection. (D) The percentage of GFP-expressing cells was 505 
monitored over a period of 35 days.  506 
 507 
Fig. 3. Expression of itEBLN protects against cell-to-cell transmission of BDV.  (A) OL 508 
cells stably expressing pHA-N, pitEBLN, pNL-itEBLN and phsEBLN-1 were co-cultured 509 
with Vero cells persistently infected with rBDV P/M-GFP. Three days after co-cultivation, the 510 
cells were treated with Zeocin or G418 to eliminate the Vero cells. The GFP expression was 511 
monitored by fluorescence microscopy. The cells were photographed 24 days after 512 
co-cultivation. (B) The percentage of GFP-expressing cells was monitored over a period of 24 513 
days.  514 
 515 
Fig. 4. itEBLN is incorporated into viral RNPs and affects BDV polymerase activity.  516 
(A) Immunoprecipitation analysis of itEBLN in OL/BDV cells. OL cells persistently infected 517 
with BDV were transfected with the indicated constructs, lysed twenty-four hour after 518 
transfection and immunoprecipitated with anti-HA antibody. Empty indicates empty vector 519 
(pcDNA3)-transfected cells. BDV P was detected by anti-BDV P antibody (arrow). The 520 
asterisk indicates non-specific bands detected in all cells. BDV genomic RNA was detected 521 
by RT-PCR using primers specific for the genome sense RNA within the BDV P region. (B) 522 
Expression of itEBLN inhibits BDV polymerase activity in a minireplicon assay. HEK293T 523 
25 
 
cells were co-transfected with a set of BDV minigenome plasmids and the expression 524 
constructs for itEBLN, hsEBLN-1, BDV N and BDV X. Forty-eight hours after transfection, 525 
the cells were lysed and subjected to CAT assays. The CAT activities are expressed as the 526 
ratio relative to empty vector-cotransfected cells (Empty). The values are the mean ± SE of 527 
three independent experiments. Statistical significance was analyzed by the two-tailed t test. 528 
** p < 0.01 529 
 530 
Fig. 5. Amino acid sequence alignment of BDV N and itEBLN.  The identical amino acids 531 
in BDV N and itEBLN are shown by blue shading. The sequences of the NLS and NES and 532 
two P-binding sites (PBS-1/-2) are indicated. Arrowheads indicate the predicted amino acids 533 
residues essential for interaction with the viral RNA. The asterisks between the sequences 534 
indicate the residues predicted to be involved in the tetramerization of BDV N. Red and blue 535 
asterisks indicate residues interacting with the preceding and following crystallographic 536 
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